Protocol abstract
Nature Protocols 2, - 67 - 77 (2007)
Published online: 22 February 2007 | doi:10.1038/nprot.2007.4
Subject Categories: Cell and tissue culture | Neuroscience | Model organisms | Pharmacology and toxicology
In vivo models of proliferative vitreoretinopathy
Rajat N Agrawal1,3, Shikun He1,2,3, Christine Spee1,3, Jing Z Cui4, Stephen J Ryan1,3 & David R Hinton1,2,3
Abstract
We outline current in vitro and in vivo models for experimental proliferative vitreoretinopathy (PVR) and provide a detailed protocol of our standardized in vivo PVR model. PVR is the leading cause of failed surgical procedures for the correction of rhegmatogenous retinal detachment. The pathogenesis of this multifactorial condition is still not completely understood. Experimental models for PVR help us understand the factors that play a role in the pathogenesis of the disease process in a controlled manner and allow for reproducible preclinical assessment of novel therapeutic interventions. We describe a cell injection model in detail that uses homologous retinal pigment epithelial (RPE) cell cultures to induce PVR over a 2–8 week period.
- Department of Ophthalmology, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA.
- Department of Pathology, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA.
- Doheny Eye Institute, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA.
- Department of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver BC, V5Z 3N9, Canada.
Correspondence to: David R Hinton1,2,3 e-mail: dhinton@usc.edu
nature-products
A-Z product listing
- 1-ml pipette(VWR International)
- 100ASA (black and white) film(Eastman Kodak Co)
- 2% w/v dispase(Invitrogen Corp)
- 2.5-mm infusion cannula(Storz Ophthalmics)
- 25-gauge intravenous catheter(BD Medical)
- 27-gauge needle(BD Medical)